Premium Content Editorial content

Bispecific antibody platforms spawn dealmaking boom

Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies.

Please sign in or register for FREE

Register to BioPharma Dealmakers

From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.


No comments yet.